胰岛素抵抗
TXNIP公司
内科学
内分泌学
蛋白激酶B
多不饱和脂肪酸
六烯酸
炎症体
脂肪组织
二十碳五烯酸
化学
白色脂肪组织
胰岛素
生物
炎症
脂肪酸
生物化学
信号转导
氧化应激
医学
硫氧还蛋白
作者
Pan Zhu,Jinjie Zhang,Cen Yi,Yong Yang,Feng Wang,Kun-Peng Gu,Haitao Yang,Yunzhi Wang,Zu-Quan Zou
出处
期刊:Molecules
[Multidisciplinary Digital Publishing Institute]
日期:2022-09-27
卷期号:27 (19): 6384-6384
被引量:18
标识
DOI:10.3390/molecules27196384
摘要
High-fat (HF) diets and low-grade chronic inflammation contribute to the development of insulin resistance and type 2 diabetes (T2D), whereas n-3 polyunsaturated fatty acids (PUFAs), due to their anti-inflammatory effects, protect against insulin resistance. Interleukin (IL)-1β is implicated in insulin resistance, yet how n-3 PUFAs modulate IL-1β secretion and attenuate HF diet-induced insulin resistance remains elusive. In this study, a HF diet activated NLRP3 inflammasome via inducing reactive oxygen species (ROS) generation and promoted IL-1β production primarily from adipose tissue preadipocytes, but not from adipocytes and induced insulin resistance in wild type (WT) mice. Interestingly, endogenous synthesized n-3 polyunsaturated fatty acids (PUFAs) reversed this process in HF diet-fed fat-1 transgenic mice although the HF diet induced higher weight gain in fat-1 mice, compared with the control diet. Mechanistically, palmitic acid (PA), the main saturated fatty acid in an HF diet inactivated AMPK and led to decreased GSK-3β phosphorylation, at least partially through reducing Akt activity, which ultimately blocked the Nrf2/Trx1 antioxidant pathway and induced TXNIP cytoplasm translocation and NLRP3 inflammasome activation, whereas docosahexaenoic acid (DHA), the most abundant n-3 PUFA in fat-1 adipose tissue, reversed this process via inducing Akt activation. Our GSK-3β shRNA knockdown study further revealed that GSK-3β played a pivot role between the upstream AMPK/Akt pathway and downstream Nrf2/Trx1/TXNIP pathway. Given that NLRP3 inflammasome is implicated in the development of most inflammatory diseases, our results suggest the potential of n-3 PUFAs in the prevention or adjuvant treatment of NLRP3 inflammasome-driven diseases.
科研通智能强力驱动
Strongly Powered by AbleSci AI